FDA clears Replimune melanoma drug RP1 for continued testing
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
FDA questions the efficacy of Capricor’s Duchenne drug
The Food and Drug Administration said Monday that Capricor Therapeutics’ stem cell treatment for Duchenne muscular dystrophy did…
Measles Is Becoming So Common That Treatments May Soon Be Needed
“I think this is a real opportunity to solve a public health problem,” Saphire says. “A tool by…
Biogen Alzheimer’s drug slowed cognitive decline in midstage study
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
AstraZeneca, Ionis report major trial failure with heart disease drug
Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially…
FDA approves Vera Therapeutics kidney disease treatment
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
Anthropic, AI powerhouse, announces it will begin developing drugs of its own
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be…
Anthropic releases Claude Science, sees Claude Code level impact
Brittany Trang, Ph.D., covers AI in health and medicine: Does it actually work? Who benefits, or might be…
FDA pilot program aims to speed up early-stage clinical trials
Lizzy leads STAT’s coverage of the FDA. Her stories explore the relationship between politics and science at the…
Lilly shares safety, tolerability data on its next-gen obesity drug
Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected…
RevMed’s pancreatic cancer, Akeso, Eli Lilly: Readout Newsletter
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter…
Revolution Medicines starts early access for pancreatic cancer drug
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…